Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | GGT1 | P19440 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 2/20 | 0.43 |
| ▸ | MMP9 | P14780 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 5/20 | 0.42 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.41 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.41 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | GGH | Q92820 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15387334 | 0.88 | GGT1 (0.61) | KMT2AALOX15BLMPMP22GGT1 | |
| SCHEMBL22042 | 0.88 | KMT2A (0.45) | KMT2AALOX15BLMPMP22GGT1 | |
| SCHEMBL27546759 | 0.88 | GGT1 (0.61) | KMT2AALOX15BLMPMP22GGT1 | |
| SCHEMBL6156358 | 0.88 | KMT2A (0.45) | KMT2AALOX15BLMPMP22GGT1 | |
| SCHEMBL1226472 | 0.88 | KMT2A (0.45) | KMT2AALOX15BLMPMP22GGT1 | |
| SCHEMBL2242496 | 0.86 | NOD1 (0.46) | KMT2AALOX15BLMPMP22GGT1 | |
| SCHEMBL5023601 | 0.86 | NOD1 (0.46) | KMT2AALOX15BLMPMP22GGT1 | |
| SCHEMBL20813494 | 0.86 | SLC1A1 (0.41) | KMT2AALOX15BLMPMP22GGT1 | |
| SCHEMBL9724019 | 0.85 | KMT2A (0.42) | KMT2AALOX15BLMPMP22GGT1 | |
| SCHEMBL8633803 | 0.85 | GGT1 (0.49) | KMT2AALOX15BLMPMP22GGT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240197666-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | K-GEN THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | US | claimed |
| WO-2024064391-A2 | USE OF PROTEIN KINASE C (PKC) ACTIVATING COMPOUNDS AS AN ADJUVANT | K-GEN THERAPEUTICS, INC. (US) | 2024-03-28 | — | — | WO | claimed |
| EP-4313095-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | K-Gen Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| CN-117098544-A | Diterpenoid compounds acting on Protein Kinase C (PKC) | K-GEN治疗股份有限公司 | 2023-11-21 | — | — | CN | claimed |
| US-20220411362-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | K-GEN THERAPEUTICS, INC. | 2022-12-29 | — | — | US | claimed |
| WO-2022204327-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | K-GEN, INC. (US) | 2022-09-29 | — | — | WO | claimed |
| EP-4041268-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | K-Gen, Inc. (US) | 2022-08-17 | — | — | EP | claimed |
| CN-114786697-A | Diterpenoids acting on Protein Kinase C (PKC) | K-GEN股份有限公司 | 2022-07-22 | — | — | CN | claimed |
| US-20100029646-A1 | PRODRUGS OF DIPHENYL OX-INDOL-2-ONE COMPOUNDS | TOPO TARGET A/S (DK) | 2010-02-04 | — | — | US | claimed |
| US-20240287123-A1 | ANTIVIRAL NUCLEOSIDE ANALOGUES | VICTORIA LINK LIMITED (NZ) | 2024-08-29 | — | — | US | disclosed |
| US-20240197666-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | K-GEN THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | US | disclosed |
| EP-4351581-A1 | ANTIVIRAL NUCLEOSIDE ANALOGUES | Victoria Link Limited (NZ) | 2024-04-17 | — | — | EP | disclosed |
| WO-2024064391-A2 | USE OF PROTEIN KINASE C (PKC) ACTIVATING COMPOUNDS AS AN ADJUVANT | K-GEN THERAPEUTICS, INC. (US) | 2024-03-28 | — | — | WO | disclosed |
| EP-4313095-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | K-Gen Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20110034453-A1 | Aminoacyl Prodrug Derivatives and Medicaments for the Treatment of Thromboembolitic Disorders | BAYER HELTHCARE AG | 2011-02-10 | — | — | US | disclosed |
| US-20100273789-A1 | AMINOACYL PRODRUGS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-28 | — | — | US | disclosed |
| US-20100029646-A1 | PRODRUGS OF DIPHENYL OX-INDOL-2-ONE COMPOUNDS | TOPO TARGET A/S (DK) | 2010-02-04 | — | — | US | disclosed |
| US-7230017-B2 | Dihydropyridinone derivatives | BAYER HEALTHCARE AG (DE) | 2007-06-12 | — | — | US | disclosed |
| US-20060100207-A1 | Dihydropyridinone derivatives | BAYER HEALTHCARE AG (DE) | 2006-05-11 | — | — | US | disclosed |
| US-6376655-B1 | APPLYING EXTERNAL STIMULATION; OPTICAL ANISOTROPY | RISO NATIONAL LABORATORY (DK) | 2002-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100207-A1 | Dihydropyridinone derivatives | TNNI3, DHPS, TNNT2 | KMT2A 2664/4885ALOX15 1747/4885BLM 4655/4885 |
| US-20240287123-A1 | ANTIVIRAL NUCLEOSIDE ANALOGUES | EBNA1BP2, RPL35, RPL7 | KMT2A 4108/4885ALOX15 3707/4885BLM 941/4885 |
| US-20100273789-A1 | AMINOACYL PRODRUGS | AADAC, DNPEP, AADAT | KMT2A 1315/4885ALOX15 1251/4885BLM 4807/4885 |
| US-20220411362-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | PRKCA, PRKCH, PRKCB | KMT2A 2943/4885ALOX15 2364/4885BLM 3263/4885 |
| US-20110034453-A1 | Aminoacyl Prodrug Derivatives and Medicaments for the Treatment of Thromboembolitic Disorders | PLG, AADAC, DNPEP | KMT2A 1784/4885ALOX15 896/4885BLM 4487/4885 |
| US-20100029646-A1 | PRODRUGS OF DIPHENYL OX-INDOL-2-ONE COMPOUNDS | IDO1, IDO2, TDO2 | KMT2A 2633/4885ALOX15 2069/4885BLM 4840/4885 |
| US-20240197666-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | PRKCA, PRKCB, PRKCI | KMT2A 3236/4885ALOX15 725/4885BLM 2075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.